Rocuronium priming for tracheal intubation in COVID‐19 patients
| Autor: | Tsutomu Mieda, China Nakamura, Hiroshi Nagasaka, K. Komiyama, Hiroshi Hoshijima, M. Ozaki, Katsushi Doi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Neuromuscular Blockade
Coronavirus disease 2019 (COVID-19) business.industry medicine.medical_treatment Tracheal intubation Energy Engineering and Power Technology Case Reports Hypoxia (medical) Rapid sequence induction Fuel Technology Respiratory failure Anesthesia medicine Rocuronium medicine.symptom business Priming (psychology) medicine.drug |
| Zdroj: | Anaesthesia Reports Anaesth Rep |
| ISSN: | 2637-3726 |
| DOI: | 10.1002/anr3.12060 |
| Popis: | Summary Priming doses of non-depolarising neuromuscular blocking drugs given before administration of anaesthetic agents have been used to hasten the onset of neuromuscular blockade In the settings of coronavirus disease 2019 (COVID-19), this could be used to reduce the apnoeic, and potentially aerosol-generating, window To our knowledge, we report the first cases of tracheal intubation with rocuronium for COVID-19 using the priming principle Both patients needed their tracheas intubated for severe hypoxia using a rapid sequence induction technique with a priming dose of rocuronium Despite adequate pre-oxygenation a sudden, unexpected fall in arterial oxygen saturations was observed in both patients after administration of a priming dose of 2 mg of rocuronium Clinicians should consider this possible risk associated with priming doses of neuromuscular blocking drugs in the management of patients with respiratory failure due to COVID-19 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text